Mount Sinai receives $500,000 SU2C grant to identify therapeutic combinations for KRAS-mutant lung cancers

Mount Sinai is leading a team of lung cancer researchers that has been awarded a three-year, $500,000 grant from Stand Up To Cancer to explore therapeutic approaches to lung tumors with mutations in the KRAS gene, an undertaking that could have a significant impact for a large population of cancer patients who currently lack effective treatment options.

Related Keywords

Fredr Hirsch ,Benjamind Hopkins ,Joe Lowe ,Davidh Cogan ,Anne Murnick Cogan ,Emily Henderson ,Tisch Cancer Institute ,Jazz Pharmaceuticals ,Langone Perlmutter Cancer Center ,Icahn School Of Medicine At Mount Sinai ,Genomic Sciences ,Oncological Sciences ,Department Of Medicine ,Division Of Hematology ,Principal Investigator ,Executive Director ,Thoracic Oncology ,Louis Price Professor ,Medical Oncology ,Icahn School ,Mount Sinai ,Kwok Kin Wong ,Perlmutter Cancer Center ,Assistant Professor ,Icahn Mount Sinai ,Functional Genomics Pipeline ,Tisch Cancer ,Stand Up To Cancer ,Cancer ,Catalyst ,Fell ,Children ,Gene ,Genomics ,Geriatrics ,Health Care ,Hematology ,Hospital ,Lung Cancer ,Medicine ,Utation ,Ncology ,Research ,Surgery ,Herapeutics ,Humor ,